Morningstar Investor users sign in here.
TOPIC

IMMUNOGLOBINS News & Analysis

25 reasons why CSL is a compelling biotech investment
Stocks
25 reasons why CSL is a compelling biotech investment
Life-changing blood treatments and staggering compound average annual share price growth of 25 per cent since floating on the ASX a quarter-century...
Glenn Freeman | 15 October 2019
Earnings wrap: CSL, Pact Group
Stocks
Earnings wrap: CSL, Pact Group
CSL's profit boost and solid outlook have earned it a fair value upgrade, while Pact Group remains undervalued despite a dividend cut and debt woes.
Lex Hall | 15 August 2019